Reflection of successful anticancer drug development processes in the literature.
Drug Discov Today
; 21(11): 1740-1744, 2016 11.
Article
en En
| MEDLINE
| ID: mdl-27443674
ABSTRACT
The development of cancer drugs is time-consuming and expensive. In particular, failures in late-stage clinical trials are a major cost driver for pharmaceutical companies. This puts a high demand on methods that provide insights into the success chances of new potential medicines. In this study, we systematically analyze publication patterns emerging along the drug discovery process of targeted cancer therapies, starting from basic research to drug approval - or failure. We find clear differences in the patterns of approved drugs compared with those that failed in Phase II/III. Feeding these features into a machine learning classifier allows us to predict the approval or failure of a targeted cancer drug significantly better than educated guessing. We believe that these findings could lead to novel measures for supporting decision making in drug development.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Edición
/
Aprobación de Drogas
/
Descubrimiento de Drogas
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Drug Discov Today
Asunto de la revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2016
Tipo del documento:
Article